Literature DB >> 17984680

Platelet-derived growth factor promotes repair of chronically demyelinated white matter.

Adam C Vana1, Nicole C Flint, Norah E Harwood, Tuan Q Le, Marcus Fruttiger, Regina C Armstrong.   

Abstract

In multiple sclerosis, remyelination becomes limited after repeated or prolonged episodes of demyelination. To test the effect of platelet-derived growth factor-A (PDGF-A) in recovery from chronic demyelination we induced corpus callosum demyelination using cuprizone treatment in hPDGF-A transgenic (tg) mice with the human PDGF-A gene under control of an astrocyte-specific promoter. After chronic demyelination and removal of cuprizone from the diet, remyelination and oligodendrocyte density improved significantly in hPDGF-A tg mice compared with wild-type mice. In hPDGF-A tg mice, oligodendrocyte progenitor density and proliferation values were increased in the corpus callosum during acute demyelination but not during chronic demyelination or the subsequent recovery period, compared with hPDGF-A tg mice without cuprizone or to treatment-matched wild-type mice. Proliferation within the subventricular zone and subcallosal zone was elevated throughout cuprizone treatment but was not different between hPDGF-A tg and wild-type mice. Importantly, hPDGF-A tg mice had reduced apoptosis in the corpus callosum during the recovery period after chronic demyelination. Therefore, PDGF-A may support oligodendrocyte generation and survival to promote remyelination of chronic lesions. Furthermore, preventing oligodendrocyte apoptosis may be important not only during active demyelination but also for supporting the generation of new oligodendrocytes to remyelinate chronic lesions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984680      PMCID: PMC2788485          DOI: 10.1097/NEN.0b013e3181587d46

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  52 in total

1.  Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells.

Authors:  G Wolswijk
Journal:  J Neurosci       Date:  1998-01-15       Impact factor: 6.167

2.  Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-beta1 gene expression during remyelination of experimentally-induced spinal cord demyelination.

Authors:  G L Hinks; R J Franklin
Journal:  Mol Cell Neurosci       Date:  1999-08       Impact factor: 4.314

3.  Platelet-derived growth factor is a survival factor for PSA-NCAM+ oligodendrocyte pre-progenitor cells.

Authors:  J B Grinspan; B Franceschini
Journal:  J Neurosci Res       Date:  1995-07-01       Impact factor: 4.164

4.  In vivo proliferation of oligodendrocyte progenitors expressing PDGFalphaR during early remyelination.

Authors:  J M Redwine; R C Armstrong
Journal:  J Neurobiol       Date:  1998-11-15

5.  Patterns of oligodendroglia pathology in multiple sclerosis.

Authors:  K Ozawa; G Suchanek; H Breitschopf; W Brück; H Budka; K Jellinger; H Lassmann
Journal:  Brain       Date:  1994-12       Impact factor: 13.501

6.  Expression of carbonic anhydrase II mRNA and protein in oligodendrocytes during toxic demyelination in the young adult mouse.

Authors:  F A Tansey; H Zhang; W Cammer
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

7.  The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor.

Authors:  Jeremy Garwood; Emmanuel Garcion; Alexandre Dobbertin; Nicolas Heck; Valerie Calco; Charles ffrench-Constant; Andreas Faissner
Journal:  Eur J Neurosci       Date:  2004-11       Impact factor: 3.386

8.  Astroglial control of oligodendrocyte survival mediated by PDGF and leukemia inhibitory factor-like protein.

Authors:  A L Gard; M R Burrell; S E Pfeiffer; J S Rudge; W C Williams
Journal:  Development       Date:  1995-07       Impact factor: 6.868

9.  Differentiation and death of premyelinating oligodendrocytes in developing rodent brain.

Authors:  B D Trapp; A Nishiyama; D Cheng; W Macklin
Journal:  J Cell Biol       Date:  1997-04-21       Impact factor: 10.539

10.  Defective oligodendrocyte development and severe hypomyelination in PDGF-A knockout mice.

Authors:  M Fruttiger; L Karlsson; A C Hall; A Abramsson; A R Calver; H Boström; K Willetts; C H Bertold; J K Heath; C Betsholtz; W D Richardson
Journal:  Development       Date:  1999-02       Impact factor: 6.868

View more
  43 in total

Review 1.  Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury.

Authors:  Arsalan Alizadeh; Soheila Karimi-Abdolrezaee
Journal:  J Physiol       Date:  2016-03-29       Impact factor: 5.182

Review 2.  Cell therapy for multiple sclerosis.

Authors:  Tamir Ben-Hur
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

3.  Visualization of the Breakdown of the Axonal Transport Machinery: a Comparative Ultrastructural and Immunohistochemical Approach.

Authors:  Sebastian Rühling; Franziska Kramer; Selina Schmutz; Sandra Amor; Zhan Jiangshan; Christoph Schmitz; Markus Kipp; Tanja Hochstrasser
Journal:  Mol Neurobiol       Date:  2018-09-21       Impact factor: 5.590

4.  Transplantation of Induced Pluripotent Stem Cell-Derived Neural Stem Cells Mediate Functional Recovery Following Thoracic Spinal Cord Injury Through Remyelination of Axons.

Authors:  Ryan P Salewski; Robert A Mitchell; Lijun Li; Carl Shen; Maria Milekovskaia; Andras Nagy; Michael G Fehlings
Journal:  Stem Cells Transl Med       Date:  2015-05-15       Impact factor: 6.940

5.  Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosis.

Authors:  Francesco Mori; Carolina G Nicoletti; Silvia Rossi; Caterina Motta; Hajime Kusayanagi; Alessandra Bergami; Valeria Studer; Fabio Buttari; Francesca Barbieri; Sagit Weiss; Robert Nisticò; Gianvito Martino; Roberto Furlan; Diego Centonze
Journal:  Neuromolecular Med       Date:  2014-03-27       Impact factor: 3.843

Review 6.  The role of growth factors as a therapeutic approach to demyelinating disease.

Authors:  Yangyang Huang; Cheryl F Dreyfus
Journal:  Exp Neurol       Date:  2016-03-22       Impact factor: 5.330

7.  Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

8.  Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS.

Authors:  Regina C Armstrong
Journal:  Future Neurol       Date:  2007-11

9.  A cord blood monocyte-derived cell therapy product accelerates brain remyelination.

Authors:  Arjun Saha; Susan Buntz; Paula Scotland; Li Xu; Pamela Noeldner; Sachit Patel; Amy Wollish; Aruni Gunaratne; Tracy Gentry; Jesse Troy; Glenn K Matsushima; Joanne Kurtzberg; Andrew E Balber
Journal:  JCI Insight       Date:  2016-08-18

10.  Fibroblast growth factor signaling in oligodendrocyte-lineage cells facilitates recovery of chronically demyelinated lesions but is redundant in acute lesions.

Authors:  Miki Furusho; Aude J Roulois; Robin J M Franklin; Rashmi Bansal
Journal:  Glia       Date:  2015-04-22       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.